Mölnlycke successfully prices a EUR 500M bond maturing 2034

Gothenburg, 4 June 2024: Mölnlycke, a world-leading MedTech company, has successfully raised EUR 500M in the corporate bond market under its Euro Medium Term Note (EMTN) programme. The bond has a 10-year tenor with an annual fixed coupon of 4.25%, corresponding to mid swaps of +1.55 percentage points.

The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%.

The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile.

The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange.

BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.

-Ends-

Liz Neal
Communications Director
liz.neal@molnlycke.com

About Mölnlycke^®
Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.

Mölnlycke^® employs around 8,400 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke^® is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www www.molnlycke.com